864780-61-0

Basic information

• Product Name: 4-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-yl]-6-(4-hydroxy-3,5-dimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyridazin-3-one
• Synonyms: 4-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-yl]-6-(4-hydroxy-3,5-dimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyridazin-3-one
• CAS NO: 864780-61-0
• Molecular Weight: 627.331
• Mol File: 864780-61-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-yl]-6-(4-hydroxy-3,5-dimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyridazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-yl]-6-(4-hydroxy-3,5-dimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyridazin-3-one(864780-61-0)
• EPA Substance Registry System: 4-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-yl]-6-(4-hydroxy-3,5-dimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyridazin-3-one(864780-61-0)

Safety Data

• Hazardous Substances Data: 864780-61-0(Hazardous Substances Data)

Upstream product

• 269410-25-5 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenol 
• 864780-59-6 6-chloro-4-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-yl]-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyridazin-3-one 

Relevant articles and documents

4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS

The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them for the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. T

4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS

The invention relates to compounds of general formula (I), wherein substituents A, B, D, E, Rl and R2 are defined in the description, in addition to the physiologically compatible salts thereof, methods for the production of said compounds and the use thereof as medicaments. Said compounds are kinase inhibitors, particularly inhibitors of kinase GSK-3? (glycogensynthase kinase-3?).